To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...

The new findings, published in Cell Systems, could eventually point toward new ways of controlling macrophage activity to treat infections or autoimmune diseases. "It turns out that macrophages ...

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for the anti-cluster of differentiation 24 (CD24) macrophage checkpoint blocker PHST001, aimed at treating advanced ...

Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide. Macrophages are important components ...

New work is showing how this process can differ between dead and viable bacteria and the effect this distinction has on regulating immune responses and the immunometabolism of the macrophage.

Researchers at the Korea Research Institute of Chemical Technology (KRICT), led by Dr. Chi Hoon Park, have successfully ...

The polarization response of macrophages seeded on titanium materials is influenced by multiple factors, and artificial intelligence can assist in extracting the key features of implant materials for ...

Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors ...

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.

With a three-minute presentation on cancer research, Kirstin Rollins, a PhD student in the Department of Molecular, Cellular, ...